Video
Author(s):
“We really felt that this was an important question to ask because we know that OAB therapy adherence is associated with improvements in urinary symptoms, quality of life, and decreased OAB-related health care costs,” says Ekene Enemchukwu, MD, MPH.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
In this video, Ekene Enemchukwu, MD, MPH, discusses the background of the study, “Identifying navigator impact on utilization of onabotulinumtoxina as a 3rd line treatment in overactive bladder: A retrospective database study in the United States” This study was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Enemchukwu is a pelvic reconstruction surgeon at Stanford Health Care, and an assistant professor of urology and obstetrics and gynecology at the Stanford University School of Medicine in California.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
SBRT may offer a safe alternative to CFRT after prostatectomy
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
Real-time IRP monitoring may redefine safety and scope of flexible ureteroscopy
2 Commerce Drive
Cranbury, NJ 08512